Survival of patients with visceral metastatic melanoma from an occult primary lesion : A retrospective matched cohort studyG.VIJUK; COATES, A. S.Annals of oncology. 1998, Vol 9, Num 4, pp 419-422, issn 0923-7534Article

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerGRUBER, G; COLE, B. F; FEV, M. F et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1393-1401, issn 0923-7534, 9 p.Article

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialMAURIAC, L; KESHAVIAH, A; NOGARET, J.-M et al.Annals of oncology. 2007, Vol 18, Num 5, pp 859-867, issn 0923-7534, 9 p.Article

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study) : a randomised controlled trial. CommentaryBOCCARDO, Francesco; RUBAGOTTI, Alessandra; DELOZIER, T et al.Lancet (British edition). 2007, Vol 369, Num 9561, issn 0140-6736, 533-535,559-570 [15 p.]Article

Risk factors for locoregional recurrence among breast Cancer patients: Results from international breast Cancer Study Group trials I through VIIWALLGREN, A; BONETTI, M; FORBES, J. F et al.Journal of clinical oncology. 2003, Vol 21, Num 7, pp 1205-1213, issn 0732-183X, 9 p.Article

Clinical relevance of single item quality of life indicators in cancer clinical trialsBERNHARD, J; SULLIVAN, M; HÜRNY, C et al.British journal of cancer. 2001, Vol 84, Num 9, pp 1156-1165, issn 0007-0920Article

Redressing the balance #75 the ethics of not entering an eligible patient on a randomised clinical trial : point of viewSEGELOV, E; TATTERSALL, M. H. N; COATES, A. S et al.Annals of oncology. 1992, Vol 3, Num 2, pp 103-105, issn 0923-7534Article

Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanomaROSENTHAL, M. A; BULL, C. A; COATES, A. S et al.European journal of cancer (1990). 1991, Vol 27, Num 12, pp 1564-1566, issn 0959-8049Article

Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantroneSTUART-HARRIS, R; SIMES, R. J; COATES, A. S et al.European journal of cancer & clinical oncology. 1987, Vol 23, Num 5, pp 557-561, issn 0277-5379Article

Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancerSIMES, R. J; TATTERSALL, M. H. N; COATES, A. S et al.British medical journal (1857). 1986, Vol 293, Num 6554, pp 1065-1068, issn 0007-1447Article

Premenopausal endocrine-responsive early breast cancer : who receives chemotherapy?REGAN, M. M; PAGANI, O; CASTIGLIONE-GERTSCH, M et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1231-1241, issn 0923-7534, 11 p.Article

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)PESTALOZZI, B. C; ZAHRIEH, D; SIMONCINI, E et al.Annals of oncology. 2006, Vol 17, Num 6, pp 935-944, issn 0923-7534, 10 p.Article

First-select the target : better choice of adjuvant treatments for breast cancer patientsGOLDHIRSCH, A; COATES, A. S; GELBER, R. D et al.Annals of oncology. 2006, Vol 17, Num 12, pp 1772-1776, issn 0923-7534, 5 p.Article

Meeting highlights : International expert consensus on the primary therapy of early breast cancer 2005GOLDHIRSCH, A; GLICK, J. H; GELBER, R. D et al.Annals of oncology. 2005, Vol 16, Num 10, pp 1569-1583, issn 0923-7534, 15 p.Article

Patients' preferences for adjuvant chemotherapy in early breast cancer : what makes AC and CMF worthwhile now?DURIC, V. M; STOCKIER, M. R; HERITIER, S et al.Annals of oncology. 2005, Vol 16, Num 11, pp 1786-1794, issn 0923-7534, 9 p.Article

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer : role of endocrine responsiveness of the tumorCOLLEONI, M; LI, S; PAGANI, O et al.Annals of oncology. 2005, Vol 16, Num 5, pp 716-725, issn 0923-7534, 10 p.Article

Factors affecting baseline quality of life in two international adjuvant breast cancer trialsBERNHARD, J; HÜRNY, C; GOLDHIRSCH, A et al.British journal of cancer. 1998, Vol 78, Num 5, pp 686-693, issn 0007-0920Article

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer : A phase III randomized trialBYRNE, M. J; GEBSKI, V; STEWART, J et al.Journal of clinical oncology. 1997, Vol 15, Num 9, pp 3141-3148, issn 0732-183XArticle

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancerHÜRNY, C; BERNHARD, J; GOLDHIRSCH, A et al.Lancet (British edition). 1996, Vol 347, Num 9011, pp 1279-1284, issn 0140-6736Article

Routine tests during follow-up of patients after primary treatment for operable breast cancerCRIVELLARI, D; PRICE, K. N; CORTES-FUNES, H et al.Annals of oncology. 1995, Vol 6, Num 8, pp 769-776, issn 0923-7534Article

Oral cyclophosphamide for the management of hormone-refractory prostate cancerRAGHAVAN, D; COX, K; PEARSON, B. S et al.British journal of urology (Print). 1993, Vol 72, Num 5, pp 625-628, issn 0007-1331, 1Article

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinomaPAGE, J. P; LEVI, J. A; WOODS, R. L et al.Cancer treatment reports. 1985, Vol 69, Num 1, pp 105-107, issn 0361-5960Article

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013GOLDHIRSCH, A; WINER, E. P; COATES, A. S et al.Annals of oncology. 2013, Vol 24, Num 9, pp 2206-2223, issn 0923-7534, 18 p.Article

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerVIALE, G; GIOBBIE-HURDER, A; PRICE, K. N et al.Annals of oncology. 2010, Vol 21, Num 2, pp 245-254, issn 0923-7534, 10 p.Article

Page / 3